Author: Sugiyama, Michael G.; Cui, Haotian; Redka, Dar’ya S.; Karimzadeh, Mehran; Rujas, Edurne; Maan, Hassaan; Hayat, Sikander; Cheung, Kyle; Misra, Rahul; McPhee, Joseph B.; Viirre, Russell D.; Haller, Andrew; Botelho, Roberto J.; Karshafian, Raffi; Sabatinos, Sarah A.; Fairn, Gregory D.; Tonekaboni, Seyed Ali Madani; Windemuth, Andreas; Julien, Jean-Philippe; Shahani, Vijay; MacKinnon, Stephen S.; Wang, Bo; Antonescu, Costin N.
                    Title: Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease  Cord-id: ohfqkvas  Document date: 2021_4_13
                    ID: ohfqkvas
                    
                    Snippet: The COVID-19 pandemic has led to an urgent need for the identification of new antiviral drug therapies that can be rapidly deployed to treat patients with this disease. COVID-19 is caused by infection with the human coronavirus SARS-CoV-2. We developed a computational approach to identify new antiviral drug targets and repurpose clinically-relevant drug compounds for the treatment of COVID-19. Our approach is based on graph convolutional networks (GCN) and involves multiscale host-virus interact
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: The COVID-19 pandemic has led to an urgent need for the identification of new antiviral drug therapies that can be rapidly deployed to treat patients with this disease. COVID-19 is caused by infection with the human coronavirus SARS-CoV-2. We developed a computational approach to identify new antiviral drug targets and repurpose clinically-relevant drug compounds for the treatment of COVID-19. Our approach is based on graph convolutional networks (GCN) and involves multiscale host-virus interactome analysis coupled to off-target drug predictions. Cellbased experimental assessment reveals several clinically-relevant repurposing drug candidates predicted by the in silico analyses to have antiviral activity against human coronavirus infection. In particular, we identify the MET inhibitor capmatinib as having potent and broad antiviral activity against several coronaviruses in a MET-independent manner, as well as novel roles for host cell proteins such as IRAK1/4 in supporting human coronavirus infection, which can inform further drug discovery studies.
 
  Search related documents: 
                                Co phrase  search for related documents- activation function and adaptive immune response: 1, 2, 3, 4
  - activation function and adaptor protein: 1
  - activation function and local global: 1
  - activation function and loss function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
  - activation function and machine ml learning: 1, 2, 3
  - activation function relu and loss function: 1
  - activation function relu and machine ml learning: 1
  - acute respiratory syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
  - acute respiratory syndrome and adaptor protein: 1, 2, 3, 4, 5
  - acute respiratory syndrome and additional drug: 1, 2, 3, 4, 5, 6
  - acute respiratory syndrome and adjacent cell: 1, 2
  - acute respiratory syndrome and live virus infection: 1, 2, 3, 4, 5
  - acute respiratory syndrome and local global: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
  - acute respiratory syndrome and loss function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
  - acute respiratory syndrome and low micromolar range: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
  - acute respiratory syndrome and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
  - acute respiratory syndrome and luciferase reporter gene: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
  - acute respiratory syndrome and lysosomal exocytosis: 1
  - acute respiratory syndrome and machine ml learning: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date